pyrazines has been researched along with Red-Cell Aplasia, Pure in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khan, F; Linden, MA; Vercellotti, GM; Zantek, ND | 1 |
| Koh, LP; Poon, LM | 1 |
2 other study(ies) available for pyrazines and Red-Cell Aplasia, Pure
| Article | Year |
|---|---|
Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO-incompatible haematopoietic stem cell transplantation.
Topics: Antineoplastic Agents; Blood Group Incompatibility; Boronic Acids; Bortezomib; Humans; Injections, Subcutaneous; Male; Middle Aged; Pyrazines; Red-Cell Aplasia, Pure | 2014 |
Successful treatment of isohemagglutinin-mediated pure red cell aplasia after ABO-mismatched allogeneic hematopoietic cell transplant using bortezomib.
Topics: ABO Blood-Group System; Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Pyrazines; Red-Cell Aplasia, Pure; Transplantation, Homologous | 2012 |